CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
Ondansetrondrug
Likely dose
Ondansetron 15-minute intravenous infusion (single dose)AI-extracted
Key inclusion· 3
  • Age 18–70 years
  • Planned hip or knee arthroplasty with spinal anesthesia
  • Ability to provide informed consent
Key exclusion· 7
  • History of or current hepatic or renal insufficiency
  • BMI ≥33
  • Heart failure or active arrhythmias
  • Severe systemic disease that is a constant threat to life

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02901054
NCT02901054N/ACompleted

Investigation of Cerebrospinal Fluid (CSF) Pharmacokinetics of Ondansetron

Washington University School of Medicine·interventional·Posted Sep 15, 2016·Updated Dec 27, 2019

In Brief

A clinical study evaluating Ondansetron for Pain. Completed, enrolled 19 participants across 1 site.

Detailed Summary

Serotonergic 5-HT3 receptors in the central nervous system are involved in pain processing after nerve injury. We are interested in learning if 5-HT3 receptor antagonist ondansetron might be an appropriate drug for treating pain after nerve injury (neuropathic pain), by investigating its bio-distribution in the cerebro-spinal fluid, and the genetic variability that may affect that distribution. Study procedures will include iv ondansetron administration, serial blood draws, cerebrospinal fluid (CSF) sampling, pregnancy testing, and possible ECG.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedSep 15, 2016
Enrollment StartAug 25, 2016
Primary CompletionNov 17, 2016
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 9.8 years ago

Interventions

Ondansetrondrug

A single 15-min intravenous infusion of ondansetron